Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics)
FDA requires new Boxed Warnings and patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms
Lantus (insulin glargine)
FDA reviewing safety data regarding possible risk for cancer in patient with diabetes.
FDA panel recommends banning Vicodin, Percocet; lowering other doses
Concerned over potentially deadly overdoses of acetaminophen, government experts are proposing new restrictions on the most widely-used painkiller.
Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer
NEW YORK–(BUSINESS WIRE)–Jun 30, 2009 - Pfizer Inc announced today the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus…
Collegium Pharmaceutical Announces the Sale of AllerNaze to Lupin
CUMBERLAND, R.I.–(BUSINESS WIRE)–Jun 30, 2009 - Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that Lupin has acquired all worldwide rights to AllerNaze™ (triamcinolone acetonide, USP) Nasal Spray, 50…
UCB (BE) - UCB and Biogen Idec Discontinue Phase II Clinical Trial of CDP323
Preliminary interim efficacy analysis showed no clinically relevant benefit for patients
BRUSSELS (Belgium), 30 June 2009 at 10:30 pm CEST - press release, regulated information - UCB and Biogen Idec announced today the discontinuation of the Phase…
Study explains Ambien side effects
A new study in mice may help explain some of the rare but strange side effects in people taking the sleep drug Ambien, including sleep walking, midnight binges and even driving while not fully awake.
Possible Case: Pull Vicodin, Percocet
Expert Panel Advises FDA
Abbott plans to appeal $1.67 billion patent order
Abbott Laboratories plans to appeal a jury’s $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.
BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement
Merged Company Will Focus on LibiGel® in Phase III Clinical Studies for Female Sexual Dysfunction and Seek Future Opportunities for GVAX Immunotherapies
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jun 30, 2009 -…